Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients

Bordignon, María Belén; Viglietti, Ayelen Ivana Pesce; Juliá, Estefanía Paula; Sánchez, María Belén; Rölle, Alexander; Mandó, Pablo; Sabatini, Luciana; Ostinelli, Alexis; Rizzo, Manglio; Barrio, María Marcela; Mordoh, José; Fainboim, Leonardo; Levy, Estrella Mariel

doi:10.1007/s00262-023-03448-w

Cited by 2 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bordignon et al (2023) [ 83 ] iterated that 72% of HCMV+ human epidermal growth factor receptor-2 positive (HER2+) breast cancer patients had an adaptive NK cell population that is characterized by NKG2C+ FCεRγ-. Interestingly, they further exclaimed that although this subset of cells produced more IFN-γ than NKG2C- FCεRγ+ NK cells, IFN-γ production was only enhanced in NK cells that expressed NKG2C+ and FCεRγ-in chorus, while the presence of a single NKG2C marker was sufficient to elicit higher functionally in healthy individuals.…”

Section: Introductionmentioning

confidence: 99%

Adaptive natural killer cell expression in response to cytomegalovirus infection in blood and solid cancer

Okpoluaefe,

Ismail,

Mohamed

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Adaptive natural killer cell expression in response to cytomegalovirus infection in blood and solid cancer

Okpoluaefe,

Ismail,

Mohamed

et al. 2024

Heliyon

View full text Add to dashboard Cite

In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pertuzumab

Pesce Viglietti,

Bordignon,

Ostinelli

et al. 2024

IJMS

View full text Add to dashboard Cite

Currently, therapy for early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) is based on the combination of trastuzumab and pertuzumab plus chemotherapy in a neoadjuvant regimen. The INMUNOHER study aimed to detect immunological markers in peripheral blood and their association with treatment response. Sixty-two HER2+ BC patients were recruited. Pre-treatment samples were obtained before the start of treatment, while post-treatment samples were obtained after completing therapy and before surgery and were analyzed by flow cytometry. The pathologic complete response (pCR) rate achieved was 82.3%. The expression of the NKp30, PD-1, and TIM-3 receptors was reduced in the Natural Killer (NK)-CD56dim subset of patients who did not achieve pCR. Following therapy, many changes were found in leukocytes, including alterations in T cell lymphocyte proportions. Also, the percentage of NK cells decreased, and several phenotypic changes were observed in this population. After treatment, IFN-γ production by NK cells against HER2+-cells with or without trastuzumab was significantly reduced. HER2-targeted therapy plus chemotherapy demonstrated high efficacy in most patients, reducing the statistical power for finding immunological markers. However, NK subset phenotypes correlated better with response groups, and numerous changes in the percentage of leukocytes and T and NK cells, as well as changes in the functionality of NK cells, were observed in most patients after treatment, encouraging further research into these immune populations.

show abstract

Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients

Cited by 2 publications

References 47 publications

Adaptive natural killer cell expression in response to cytomegalovirus infection in blood and solid cancer

Adaptive natural killer cell expression in response to cytomegalovirus infection in blood and solid cancer

In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pertuzumab

Contact Info

Product

Resources

About